Skip to content

CEO Spotlight: James West

CEO Spotlight: James West

As a former academic coordinator for the City University of New York Research Foundation and Medgar Evers College, CEO and co-founder of Arfinn Med, James West, has extensive experience in adult education and professional training programming. James put this extensive education to good use when he noticed that there was a direct need for a new Electronic Medical Record system in the medical marijuana industry.

James first became interested in CBD and its benefits after coming across a number of news stories covering the revolutionary medical treatment. To start his journey into the medical marijuana industry, James conducted research on his own and spoke with numerous medical professionals on the topic. While researching, he realized that many medical professionals were interested in prescribing medical cannabis, but lacked access to sufficient research and data.

To help fix this issue, James created Arfinn Med, the first ever clinician-based medical professional and patient efficacy portal for medical marijuana treatment. With his experience top-of-mind, James’ objective for creating the Arfinn Med portal was to provide a digital warehouse of data from credible medical sources.

Arfinn Med is a free service that welcomes any and all licensed medical professionals to register, no matter the state of practice and medical marijuana legalization. Some additional features the portal provides Arfinn Med members include direct patient updates, the ability to view previous case studies conducted by licensed medical professionals, industry updates and so much more!

If you’re ready to join a nationwide network of licensed medical professionals to learn and share best practices and treatment efficacies for medical marijuana, join Arfinn Med for free today.

Stories you may be interested in

Cannabis and Seniors

As more and more research comes out regarding the medical benefits of cannabis, it’s important to keep up with new research as it becomes available.  Here at Arfinn Med, we constantly review new studies and look at our own deidentified efficacy data to try to find any additional insights we can relay to our registered…
Read More

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More

REGISTRATION NOW OPEN: Arfinn Med Medical Cannabis Efficacy Portal for Licensed Medical Professionals

Arfinn Med, the first clinician-based medical professional and patient efficacy portal for medical cannabis treatments, is now open for registrations from licensed medical professionals. The free collaborative portal allows medical professionals to register, share, research and communicate HIPAA-compliant benchmark data for medical cannabis treatments. As a free tool for physicians, Arfinn Med offers a new…
Read More

Alternative Mississippi medical marijuana program barely wins approval from Senate

JACKSON • Legislation that would create a new medical marijuana program in Mississippi if the voter-approved Initiative 65 is overturned in court cleared the state Senate on the second try last week early on Friday morning. Senate Bill 2765, the Mississippi Medical Cannabis Act, failed by a single vote Thursday evening. But six hours later, after…
Read More

Data Migration and Mapping Functions

Medical software does not have a good reputation for user experience and intuitive design. It can seem like a full-time job just learning how to use these software solutions.  In fact, according to a study from Stanford Medicine, 74% of doctors responded that their EMR increased the number of hours they work every day and…
Read More

After marijuana edibles helped dying Holocaust survivor battle Alzheimer’s, his family’s foundation pushes for more research

A Massachusetts family’s experience giving marijuana edibles to their dying patriarch is set to kick off a desperately needed investigation into how cannabis might treat some of the more troubling symptoms of Alzheimer’s disease, a condition that affects 5.7 million Americans. Read the full story here.
Read More